CMN Weekly (23 February 2024) - Your Weekly CRISPR Medicine News

Some of the best links we picked up around the internet

By: Gorm Palmgren - Feb. 23, 2024
News

#CRISPRMED24

Top picks

Research

Industry

Detection

CRISPR screens

Reviews

Perspectives

  • A news feature in Nature, "Move over, CRISPR: RNA-editing therapies pick up steam", describes how two RNA-editing therapies for genetic diseases have gained approval for clinical trials in the past few months, raising hopes for safer treatments. The RNA-editing approaches differ in the two trials: One is exploring single-base editing to treat a genetic lung and liver disorder called alpha-1 antitrypsin deficiency (AATD), while the other approach, called RNA exon editing, changes thousands of genetic letters in an RNA molecule at once and aims at treating disorders caused by multiple mutations in a person's genome.

News from CRISPR Medicine News

To get more of the CRISPR Medicine News delivered to your inbox, sign up to the free weekly CMN Newsletter here.

Tags

HashtagArticleHashtagMissing linksHashtagNewsHashtagCMN Weekly

News: CMN Weekly (23 February 2024) - Your Weekly CRISPR Medicine News
CLINICAL TRIALS
Refractory Hypercholesterolemia, NCT06451770
Sponsors:
Verve Therapeutics, Inc.
Indicator
IND Enabling
Phase I
Phase II
Phase III
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
Huntington's Disease, (NCT05032196)
Sponsors:
Wave Life Sciences Ltd.
IndicatorIndicator
IND Enabling
Phase I
Phase II
Phase III
View all clinical trials
close
Search CRISPR Medicine